Not sure where you got 9.85 ms cT1 from. In t

Not sure where you got 9.85 ms cT1 from.

In the 350mg >950ms cT1 group we achieved -68.86. That's 25x what the 700mg did. But only 1.5x what the 700mg HM did. 700 is only appropriate in the HM group. This is clear.

Not sure why you would say I think LRM is a failure. I believe dosing has a ton to do with its effectiveness in NASH though because I believe the biomarkers are valid and I've tried to make sense of them.

Quote:

---

There was a +30.37 ms difference between placebo and 700mg.

---

and there was a + 96.5 ms cT1 difference b/w placebo & 350mg >950 ms cT1 arm.

Looking at PDFF, The 700mg normal did horribly even worse than Placebo if you look at the highs but considering only the average, there was a slight benefit of 6.1% loss in fat.
The 700mg HM did the best with a loss of 28% fat or 38% better than placebo.
The 350mg >950 ms cT1 group did about 19% better than placebo.

Unless you have HM, 350 is way to go. This is clear. If you have HM go with 700mg especially if the patients are more NAFLD or mild NASH. If severe NASH, they may do better with 350mg.